Ann: OSX Enters Orthopaedic Market in Great Britain, page-2

OSX is quite the enigma.

I am not a long term share holder and absolutely bow to many with no doubt far more insight than I on the stock. Feel bad for 2019 to 2021 buyers, but this company keeps announcing positive steps in sales footprints. Its actual revenues of course far too small, but they and its sales footprint growing impressively.

That the company did not raise more recently or elaborate why is very poor governance in my opinion. The Directors have a duty of disclosure to the public owners of the company, particularly when they are running the balance sheet so close to the wind. Suspect we will get some elaboration at the earnings shortly.

I hope, but almost fear for those long term holders who've sold, its about to announce a partnership or something that will see it through to where the absolute revenues, through these continued growth rates, are approaching enough to take it cash flow positive. All too late, holders who have trimmed or exited will see the business potential they bought the company on at alas higher prices many years before I.